Announcements
- CytoSorbents Secures $20 Million Credit Facility
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
- CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
- CytoSorbents Reports First Quarter 2024 Results
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
- CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
More ▼
Key statistics
On Friday, Cytosorbents Corp (HQE1:BER) closed at 0.756, 21.54% above the 52 week low of 0.622 set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.756 |
---|---|
High | 0.756 |
Low | 0.756 |
Bid | 0.821 |
Offer | 0.859 |
Previous close | 0.758 |
Average volume | 8.33 |
---|---|
Shares outstanding | 54.31m |
Free float | 52.57m |
P/E (TTM) | -- |
Market cap | 46.70m USD |
EPS (TTM) | -0.5869 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 07:09 BST.
More ▼